<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRUVADA - emtricitabine and tenofovir disoproxil fumarate tablet, film coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TRUVADA safely and effectively. See full prescribing information for TRUVADA.<br> <br>TRUVADA<span class="Sup">®</span> (emtricitabine/tenofovir disoproxil fumarate) tablets<br>  Initial U.S. Approval: 2004</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">TRUVADA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients coinfected with HIV-1 and HBV who have discontinued TRUVADA. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="60%">
<col align="left" width="75%">
<col align="right" width="25%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Warnings and Precautions</td>
<td align="right"></td>
</tr>
<tr class="Botrule Last">
<td align="left">  New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#S5.3">5.3</a>)</td>
<td align="right">11/2009</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">TRUVADA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients coinfected with HIV-1 and HBV who have discontinued TRUVADA. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">TRUVADA, a combination of EMTRIVA and VIREAD, both nucleoside analog HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended dose: One tablet (containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) once daily taken orally with or without food. (<a href="#S2.1">2.1</a>)</li>
<li>Dose recommended in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: <br>									Creatinine clearance 30–49 mL/min: 1 tablet every 48 hours. (<a href="#S2.2">2.2</a>)<br>									 CrCl &lt;30 mL/min or hemodialysis: Do not use TRUVADA. (<a href="#S2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Can include <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>. Assess creatinine clearance (CrCl) before initiating treatment with TRUVADA. Monitor CrCl and serum phosphorus in patients at risk. Avoid administering Truvada with concurrent or recent use of nephrotoxic drugs. (<a href="#S5.3">5.3</a>)</li>
<li>Coadministration with Other Products: Do not use with drugs containing emtricitabine or tenofovir disoproxil fumarate including ATRIPLA, EMTRIVA, VIREAD; or with drugs containing lamivudine. Do not administer in combination with HEPSERA. (<a href="#S5.4">5.4</a>)</li>
<li>Decreases in bone mineral density (BMD): Consider monitoring BMD in patients with a history of pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or who are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>. (<a href="#S5.5">5.5</a>)</li>
<li>Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy. (<a href="#S5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span>: May necessitate further evaluation and treatment. (<a href="#S5.7">5.7</a>)</li>
<li>Triple nucleoside-only regimens: Early virologic failure has been reported in HIV-infected patients. Monitor carefully and consider treatment modification. (<a href="#S5.8">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥10%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#S6">6</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Didanosine: Tenofovir disoproxil fumarate increases didanosine concentrations. Use with caution and monitor for evidence of didanosine toxicity (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>) when coadministered. Consider dose reductions or discontinuations of didanosine if warranted. (<a href="#S7.1">7.1</a>)</li>
<li>Atazanavir: Coadministration decreases atazanavir concentrations and increases tenofovir concentrations. Use atazanavir with TRUVADA only with ritonavir; monitor for evidence of tenofovir toxicity. (<a href="#S7.2">7.2</a>)</li>
<li>Lopinavir/ritonavir: Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: pregnancy registry available: Enroll patients by calling 1-800-258-4263.</li>
<li>Nursing mothers: Women infected with HIV should be instructed not to breast feed. (<a href="#S8.3">8.3</a>)</li>
<li>Pediatrics: Safety and efficacy not established in patients less than 18 years of age. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Patients Coinfected with HIV-1 and HBV</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Coadministration with Other Products</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Decreases in Bone Mineral Density</a></h2>
<h2><a href="#section-5.6" class="toc"></a></h2>
<h2><a href="#section-5.7" class="toc">5.6	Fat Redistribution</a></h2>
<h2><a href="#section-5.8" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.8	Early Virologic Failure</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Adverse Reactions from Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc"></a></h2>
<h2><a href="#section-6.3" class="toc"></a></h2>
<h2><a href="#section-6.4" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Didanosine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Atazanavir</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Lopinavir/Ritonavir</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Drugs Affecting Renal Function</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.2" class="toc"></a></h2>
<h2><a href="#section-8.3" class="toc"></a></h2>
<h2><a href="#section-8.4" class="toc"></a></h2>
<h2><a href="#section-8.5" class="toc"></a></h2>
<h2><a href="#section-8.6" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.7" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.8" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.9" class="toc">8.6	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc"></a></h2>
<h2><a href="#section-9.2" class="toc"></a></h2>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc"></a></h2>
<h2><a href="#section-10.2" class="toc"></a></h2>
<h2><a href="#section-10.3" class="toc"></a></h2>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.3" class="toc"></a></h2>
<h2><a href="#section-11.4" class="toc"></a></h2>
<h2><a href="#section-11.5" class="toc"></a></h2>
<h2><a href="#section-11.6" class="toc"></a></h2>
<h2><a href="#section-11.7" class="toc"></a></h2>
<h2><a href="#section-11.8" class="toc"></a></h2>
<h2><a href="#section-11.9" class="toc"></a></h2>
<h2><a href="#section-11.10" class="toc"></a></h2>
<h2><a href="#section-11.11" class="toc"></a></h2>
<h2><a href="#section-11.12" class="toc"></a></h2>
<h2><a href="#section-11.13" class="toc"></a></h2>
<h2><a href="#section-11.14" class="toc"></a></h2>
<h2><a href="#section-11.15" class="toc"></a></h2>
<h2><a href="#section-11.16" class="toc"></a></h2>
<h2><a href="#section-11.18" class="toc"></a></h2>
<h2><a href="#section-11.19" class="toc"></a></h2>
<h2><a href="#section-11.20" class="toc"></a></h2>
<h2><a href="#section-11.21" class="toc"></a></h2>
<h2><a href="#section-11.22" class="toc"></a></h2>
<h2><a href="#section-11.23" class="toc"></a></h2>
<h2><a href="#section-11.24" class="toc"></a></h2>
<h2><a href="#section-11.25" class="toc"></a></h2>
<h2><a href="#section-11.26" class="toc"></a></h2>
<h2><a href="#section-11.27" class="toc"></a></h2>
<h2><a href="#section-11.28" class="toc"></a></h2>
<h2><a href="#section-11.29" class="toc"></a></h2>
<h2><a href="#section-11.30" class="toc"></a></h2>
<h2><a href="#section-11.31" class="toc"></a></h2>
<h2><a href="#section-11.32" class="toc"></a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.2" class="toc"></a></h2>
<h2><a href="#section-12.3" class="toc"></a></h2>
<h2><a href="#section-12.4" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Study 934</a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION and FDA-APPROVED PATIENT LABELING</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Box"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA, in combination with other antiretrovirals <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p><span class="Bold">TRUVADA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the safety and efficacy of TRUVADA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue TRUVADA. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">TRUVADA<span class="Sup">®</span>, a combination of EMTRIVA<span class="Sup">®</span> and VIREAD<span class="Sup">®</span>, is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults.</p>
<p>The following points should be considered when initiating therapy with TRUVADA for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<ul>
<li>It is not recommended that TRUVADA be used as a component of a triple nucleoside regimen.</li>
<li>TRUVADA should not be coadministered with ATRIPLA<span class="Sup">®</span>, EMTRIVA, VIREAD or lamivudine-containing products <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>In treatment experienced patients, the use of TRUVADA should be guided by laboratory testing and treatment history <span class="Italics">[See <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose</h2>
<p class="First">The dose of TRUVADA is one tablet (containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) once daily taken orally with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Significantly increased drug exposures occurred when EMTRIVA or VIREAD were administered to subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see EMTRIVA or VIREAD Package Insert]</span>. Therefore, the dosing interval of TRUVADA should be adjusted in patients with baseline creatinine clearance 30–49 mL/min using the recommendations in Table 1. These dosing interval recommendations are based on modeling of single-dose pharmacokinetic data in non-HIV infected subjects. The safety and effectiveness of these dosing interval adjustment recommendations have not been clinically evaluated in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, therefore clinical response to treatment and renal function should be closely monitored in these patients <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p>No dose adjustment is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 50–80 mL/min). Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics"> [See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1 Dosage Adjustment for Patients with Altered Creatinine Clearance</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">Creatinine Clearance (mL/min)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">≥50</th>
<th class="Rrule" align="center">30–49</th>
<th class="Rrule" align="center">&lt;30 <br> (Including Patients Requiring Hemodialysis)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Calculated using ideal (lean) body weight</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule" align="left"><span class="Bold">Recommended Dosing Interval</span></td>
<td class="Lrule Rrule" align="center">Every 24 hours</td>
<td class="Rrule" align="center">Every 48 hours</td>
<td class="Rrule" align="center">TRUVADA should not be administered.</td>
</tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TRUVADA is available as tablets. Each tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (which is equivalent to 245 mg of tenofovir disoproxil). The tablets are blue, capsule-shaped, film-coated, debossed with "GILEAD" on one side and with "701" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA, in combination with other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with TRUVADA should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Patients Coinfected with HIV-1 and HBV</h2>
<p class="First">It is recommended that all patients with HIV-1 be tested for the presence of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) before initiating antiretroviral therapy. TRUVADA is not approved for the treatment of chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the safety and efficacy of TRUVADA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued TRUVADA. In some patients infected with HBV and treated with EMTRIVA, the exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B were associated with liver decompensation and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Patients who are coinfected with HIV-1 and HBV should be closely monitored with both clinical and laboratory follow up for at least several months after stopping treatment with Truvada. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Emtricitabine and tenofovir are principally eliminated by the kidney. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span> (renal tubular injury with severe <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>), has been reported with the use of VIREAD <span class="Italics">[See <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with TRUVADA. Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients at risk for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including patients who have previously experienced renal events while receiving HEPSERA.</span></p>
<p>Dosing interval adjustment of TRUVADA and close monitoring of renal function are recommended in all patients with creatinine clearance 30–49 mL/min, <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. No safety or efficacy data are available in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who received TRUVADA using these dosing guidelines, so the potential benefit of TRUVADA therapy should be assessed against the potential risk of renal toxicity. TRUVADA should not be administered to patients with creatinine clearance &lt;30 mL/min or patients requiring hemodialysis.</p>
<p>TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Coadministration with Other Products</h2>
<p class="First">TRUVADA is a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate. TRUVADA should not be coadministered with ATRIPLA, EMTRIVA, or VIREAD. Due to similarities between emtricitabine and lamivudine, TRUVADA should not be coadministered with other drugs containing lamivudine, including Combivir (lamivudine/zidovudine), Epivir or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), or Trizivir (abacavir sulfate/lamivudine/zidovudine).</p>
<p>TRUVADA should not be administered with HEPSERA<span class="Sup">®</span> (adefovir dipivoxil).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Decreases in Bone Mineral Density</h2>
<p class="First">Bone mineral density (BMD) monitoring should be considered for HIV-1 infected patients who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients. If bone abnormalities are suspected then appropriate consultation should be obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  In a 144-week study of treatment-naive subjects, decreases in BMD were seen at the lumbar spine and hip in both arms of the study. At Week 144, there was a significantly greater mean percentage decrease from baseline in BMD at the lumbar spine in subjects receiving VIREAD + lamivudine + efavirenz compared with subjects receiving stavudine + lamivudine + efavirenz. Changes in BMD at the hip were similar between the two treatment groups. In both groups, the majority of the reduction in BMD occurred in the first 24–48 weeks of the study and this reduction was sustained through 144 weeks. Twenty-eight percent of VIREAD-treated subjects vs. 21% of the comparator subjects lost at least 5% of BMD at the spine or 7% of BMD at the hip. Clinically relevant <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (excluding fingers and toes) were reported in 4 subjects in the VIREAD group and 6 subjects in the comparator group. Tenofovir disoproxil fumarate was associated with significant increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide), suggesting increased bone turnover. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving VIREAD. The effects of VIREAD-associated changes in BMD and biochemical markers on long-term bone health and future <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk are unknown. For additional information, please consult the VIREAD prescribing information.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (associated with proximal renal tubulopathy and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) have been reported in association with the use of VIREAD <span class="Italics">[See <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.7"></a><p></p>
<h2>5.6	Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.8"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including TRUVADA. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>], which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.9"></a><p></p>
<h2>5.8	Early Virologic Failure</h2>
<p class="First">Clinical studies in HIV-infected subjects have demonstrated that certain regimens that only contain three nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing two NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance substitutions have been reported. Triple nucleoside regimens should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>Severe Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</li>
<li>Decreases in Bone Mineral Density <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> <span class="Italics">[See <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Adverse Reactions from Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most common adverse reactions (incidence ≥10%, any severity) occurring in Study 934, an active-controlled clinical study of efavirenz, emtricitabine, and tenofovir disoproxil fumarate, include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. See also <a href="#table2">Table 2</a> for the frequency of treatment-emergent adverse reactions (Grade 2–4) occurring in ≥5% of subjects treated with efavirenz, emtricitabine, and tenofovir disoproxil fumarate in this study.</p>
<p><span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span>, manifested by hyperpigmentation on the palms and/or soles was generally mild and asymptomatic. The mechanism and clinical significance are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 934 - Treatment Emergent Adverse Reactions:</span>  In Study 934, 511 antiretroviral-naive subjects received either VIREAD + EMTRIVA administered in combination with efavirenz (N=257) or zidovudine/lamivudine administered in combination with efavirenz (N=254). Adverse reactions observed in this study were generally consistent with those seen in other studies in treatment-experienced or treatment-naive subjects receiving VIREAD and/or EMTRIVA (Table 2).</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2 Selected Treatment-Emergent Adverse Reactions<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (Grades 2–4) Reported in ≥5% in Any Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">FTC + TDF + EFV<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>From Weeks 96 to 144 of the study, subjects received TRUVADA with efavirenz in place of VIREAD + EMTRIVA with efavirenz.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">General Disorders and Administration Site Condition</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Psychiatric Disorders</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Skin and Subcutaneous Tissue Disorders</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span>  Laboratory abnormalities observed in this study were generally consistent with those seen in other studies of VIREAD and/or EMTRIVA (Table 3).</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 Significant Laboratory Abnormalities Reported in ≥1% of Subjects in Any Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">FTC + TDF + EFV<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>From Weeks 96 to 144 of the study, subjects received TRUVADA with efavirenz in place of VIREAD + EMTRIVA with efavirenz.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">30%</td>
<td class="Rrule" align="center">26%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (&gt;240 mg/dL)</td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">24%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990 U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alkaline Phosphatase (&gt;550 U/L)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hemoglobin (&lt;8.0 mg/dL)</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;250 mg/dL)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> (&gt;75 RBC/HPF)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span> (≥3+)</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Fasting Triglycerides (&gt;750 mg/dL)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
<p>In addition to the events described above for Study 934, other adverse reactions that occurred in at least 5% of subjects receiving EMTRIVA or VIREAD with other antiretroviral agents in clinical trials include <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p>In addition to the laboratory abnormalities described above for Study 934, Grade 3/4 elevations of bilirubin (&gt;2.5 × ULN), pancreatic amylase (&gt;2.0 × ULN), serum glucose (&lt;40 or &gt;250 mg/dL), and serum lipase (&gt;2.0 × ULN) occurred in up to 3% of subjects treated with EMTRIVA or VIREAD with other antiretroviral agents in clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.4"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of VIREAD. No additional adverse reactions have been identified during postapproval use of EMTRIVA. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders </span><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span></p>
<p><span class="Italics">Respiratory</span>, <span class="Italics">Thoracic</span>, <span class="Italics">and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span><br> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, increased amylase, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Italics">Hepatobiliary Disorders</span><br><span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, increased liver enzymes (most commonly AST, ALT gamma GT)</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span><br> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (manifested as <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span></p>
<p><span class="Italics">Renal and Urinary Disorders</span><br><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, proximal renal tubulopathy, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (including acute cases), <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p>
<p>The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">No drug interaction studies have been conducted using TRUVADA tablets. Drug interaction studies have been conducted with emtricitabine and tenofovir disoproxil fumarate, the components of TRUVADA. This section describes clinically relevant drug interactions observed with emtricitabine and tenofovir disoproxil fumarate <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Didanosine</h2>
<p class="First">Coadministration of TRUVADA and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions.</p>
<p>When tenofovir disoproxil fumarate was administered with didanosine the C<span class="Sub">max</span> and AUC of didanosine administered as either the buffered or enteric-coated formulation increased significantly <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>. Suppression of CD4<span class="Sup">+</span> cell counts has been observed in patients receiving tenofovir DF with didanosine 400 mg daily.</p>
<p>In adults weighing &gt;60 kg, the didanosine dose should be reduced to 250 mg when it is coadministered with TRUVADA. Data are not available to recommend a dose adjustment of didanosine for patients weighing &lt;60 kg. When coadministered, TRUVADA and Videx EC may be taken under fasted conditions or with a light meal (&lt;400 kcal, 20% fat). Coadministration of didanosine buffered tablet formulation with TRUVADA should be under fasted conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Atazanavir</h2>
<p class="First">Atazanavir has been shown to increase tenofovir concentrations <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Patients receiving atazanavir and TRUVADA should be monitored for TRUVADA-associated adverse reactions. TRUVADA should be discontinued in patients who develop TRUVADA-associated adverse reactions<span class="Italics">.</span></p>
<p>Tenofovir decreases the AUC and C<span class="Sub">min </span>of atazanavir <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. When coadministered with TRUVADA, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Atazanavir without ritonavir should not be coadministered with TRUVADA<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Lopinavir/Ritonavir</h2>
<p class="First">Lopinavir/ritonavir has been shown to increase tenofovir concentrations <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Patients receiving lopinavir/ritonavir and TRUVADA should be monitored for TRUVADA-associated adverse reactions. TRUVADA should be discontinued in patients who develop TRUVADA-associated adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Drugs Affecting Renal Function</h2>
<p class="First">Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. No drug-drug interactions due to competition for renal excretion have been observed; however, coadministration of TRUVADA with drugs that are eliminated by active tubular secretion may increase concentrations of emtricitabine, tenofovir, and/or the coadministered drug. Some examples include, but are not limited to acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, and valganciclovir. Drugs that decrease renal function may increase concentrations of emtricitabine and/or tenofovir.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  The incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with emtricitabine in mice at exposures (AUC) approximately 60-fold higher and in rabbits at approximately 120-fold higher than human exposures at the recommended daily dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 times the human dose based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus due to tenofovir.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, TRUVADA should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiretroviral Pregnancy Registry: </span> To monitor fetal outcomes of pregnant women exposed to TRUVADA, an Antiretroviral Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.6"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First"><span class="Bold">Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV-1. </span>Studies in rats have demonstrated that tenofovir is secreted in milk. It is not known whether tenofovir is excreted in human milk. It is not known whether emtricitabine is excreted in human milk. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are receiving TRUVADA</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.7"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Truvada is not recommended for patients less than 18 years of age because it is a fixed-dose combination tablet containing a component, VIREAD, for which safety and efficacy have not been established in this age group.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.8"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Clinical studies of EMTRIVA or VIREAD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for the elderly patients should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.9"></a><p></p>
<h2>8.6	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">It is recommended that the dosing interval for TRUVADA be modified in patients with creatinine clearance 30–49 mL/min. TRUVADA should not be used in patients with creatinine clearance &lt;30 mL/min and in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Limited clinical experience is available at doses higher than the therapeutic dose of EMTRIVA. In one clinical pharmacology study single doses of emtricitabine 1200 mg were administered to 11 subjects. No severe adverse reactions were reported.</p>
<p>Hemodialysis treatment removes approximately 30% of the emtricitabine dose over a 3-hour dialysis period starting within 1.5 hours of emtricitabine dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether emtricitabine can be removed by peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Limited clinical experience at doses higher than the therapeutic dose of VIREAD 300 mg is available. In one study, 600 mg tenofovir disoproxil fumarate was administered to 8 subjects orally for 28 days, and no severe adverse reactions were reported. The effects of higher doses are not known.</p>
<p>Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">TRUVADA tablets are fixed dose combination tablets containing emtricitabine and tenofovir disoproxil fumarate. EMTRIVA is the brand name for emtricitabine, a synthetic nucleoside analog of cytidine. Tenofovir disoproxil fumarate (tenofovir DF) is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Both emtricitabine and tenofovir exhibit inhibitory activity against HIV-1 reverse transcriptase.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  The chemical name of emtricitabine is 5-fluoro-1-(2<span class="Italics">R</span>,5<span class="Italics">S</span>)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.</p>
<p>It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">10</span>FN<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 247.24. It has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-01.jpg"></p>
<p>Emtricitabine is a white to off-white crystalline powder with a solubility of approximately 112 mg/mL in water at 25 °C. The partition coefficient (log p) for emtricitabine is -0.43 and the pKa is 2.65.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Tenofovir disoproxil fumarate is a fumaric acid salt of the bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of tenofovir disoproxil fumarate is 9-[(<span class="Italics">R</span>)-2 [[bis[[(isopropoxycarbonyl)oxy]- methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">30</span>N<span class="Sub">5</span>O<span class="Sub">10</span>P • C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and a molecular weight of 635.52. It has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-02.jpg"></p>
<p>Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25 °C. The partition coefficient (log p) for tenofovir disoproxil is 1.25 and the pKa is 3.75. All dosages are expressed in terms of tenofovir disoproxil fumarate except where otherwise noted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2></h2>
<p class="First">TRUVADA tablets are for oral administration. Each film-coated tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, (which is equivalent to 245 mg of tenofovir disoproxil), as active ingredients. The tablets also include the following inactive ingredients:  croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch (gluten free). The tablets are coated with Opadry II Blue Y-30-10701, which contains FD&amp;C Blue #2 aluminum lake, hydroxypropyl methylcellulose 2910, lactose monohydrate, titanium dioxide, and triacetin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<p class="First">For additional information on Mechanism of Action, Antiviral Activity, Resistance and Cross Resistance, please consult the EMTRIVA and VIREAD prescribing information.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">TRUVADA is a fixed-dose combination of antiviral drugs emtricitabine and tenofovir disoproxil fumarate. <span class="Italics">[See <a href="#S12.4">Clinical Pharmacology (12.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">TRUVADA: </span> One TRUVADA tablet was bioequivalent to one EMTRIVA capsule (200 mg) plus one VIREAD tablet (300 mg) following single-dose administration to fasting healthy subjects (N=39). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:  </span>The pharmacokinetic properties of emtricitabine are summarized in Table 4. Following oral administration of EMTRIVA, emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1–2 hours post-dose. In vitro binding of emtricitabine to human plasma proteins is &lt;4% and is independent of concentration over the range of 0.02–200 µg/mL. Following administration of radiolabelled emtricitabine, approximately 86% is recovered in the urine and 13% is recovered as metabolites. The metabolites of emtricitabine include 3'-sulfoxide diastereomers and their glucuronic acid conjugate. Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion. Following a single oral dose of EMTRIVA, the plasma emtricitabine half-life is approximately 10 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate: </span> The pharmacokinetic properties of tenofovir disoproxil fumarate are summarized in Table 4. Following oral administration of VIREAD, maximum tenofovir serum concentrations are achieved in 1.0 ± 0.4 hour. In vitro binding of tenofovir to human plasma proteins is &lt;0.7% and is independent of concentration over the range of 0.01–25 µg/mL. Approximately 70–80% of the intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. Following a single oral dose of VIREAD, the terminal elimination half-life of tenofovir is approximately 17 hours.</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4 Single Dose Pharmacokinetic Parameters for Emtricitabine and Tenofovir in Adults<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Emtricitabine</th>
<th class="Rrule" align="center">Tenofovir</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>NC = Not calculated</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Median (range)</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Mean (± SD)</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Data presented as steady state values.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Fasted Oral Bioavailability<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a> (%)</td>
<td class="Rrule" align="center">92 (83.1–106.4)</td>
<td class="Rrule" align="center">25 (NC–45.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Plasma Terminal Elimination Half-Life<a href="#footnote-7" class="Sup">†</a> (hr)</td>
<td class="Rrule" align="center">10 (7.4–18.0)</td>
<td class="Rrule" align="center">17 (12.0–25.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a> (µg/mL)</td>
<td class="Rrule" align="center">1.8 ± 0.72<a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.30 ± 0.09</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AUC<a href="#footnote-8" class="Sup">‡</a> (µg<span class="Bold">∙</span>hr/mL)</td>
<td class="Rrule" align="center">10.0 ± 3.12<a href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">2.29 ± 0.69</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CL/F<a href="#footnote-8" class="Sup">‡</a> (mL/min)</td>
<td class="Rrule" align="center">302 ± 94</td>
<td class="Rrule" align="center">1043 ± 115</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CL<span class="Sub">renal</span><a href="#footnote-8" class="Sup">‡</a> (mL/min)</td>
<td class="Rrule" align="center">213 ± 89</td>
<td class="Rrule" align="center">243 ± 33</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Effects of Food on Oral Absorption</span></p>
<p>TRUVADA may be administered with or without food. Administration of TRUVADA following a high fat meal (784 kcal; 49 grams of fat) or a light meal (373 kcal; 8 grams of fat) delayed the time of tenofovir C<span class="Sub">max</span> by approximately 0.75 hour. The mean increases in tenofovir AUC and C<span class="Sub">max</span> were approximately 35% and 15%, respectively, when administered with a high fat or light meal, compared to administration in the fasted state. In previous safety and efficacy studies, VIREAD (tenofovir) was taken under fed conditions. Emtricitabine systemic exposures (AUC and C<span class="Sub">max</span>) were unaffected when TRUVADA was administered with either a high fat or a light meal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Race</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:  </span>No pharmacokinetic differences due to race have been identified following the administration of EMTRIVA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations following the administration of VIREAD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.11"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Gender</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil</span><span class="Italics"> Fumarate:</span>  Emtricitabine and tenofovir pharmacokinetics are similar in male and female subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Pediatric and Geriatric Patients</span></p>
<p>Pharmacokinetic studies of tenofovir have not been performed in pediatric subjects (&lt;18 years). Pharmacokinetics of emtricitabine and tenofovir have not been fully evaluated in the elderly (&gt;65 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.14"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></p>
<p>The pharmacokinetics of emtricitabine and tenofovir are altered in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. In subjects with creatinine clearance &lt;50 mL/min, C<span class="Sub">max</span>, and AUC<span class="Sub">0–</span><span class="Sub">∞</span> of emtricitabine and tenofovir were increased. It is recommended that the dosing interval for TRUVADA be modified in patients with creatinine clearance 30–49 mL/min. TRUVADA should not be used in patients with creatinine clearance &lt;30 mL/min and in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.15"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of tenofovir following a 300 mg dose of VIREAD have been studied in non-HIV infected subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. There were no substantial alterations in tenofovir pharmacokinetics in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with unimpaired subjects. The pharmacokinetics of TRUVADA or emtricitabine have not been studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; however, emtricitabine is not significantly metabolized by liver enzymes, so the impact of liver impairment should be limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.16"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Assessment of Drug Interactions</span></p>
<p>The steady state pharmacokinetics of emtricitabine and tenofovir were unaffected when emtricitabine and tenofovir disoproxil fumarate were administered together versus each agent dosed alone.</p>
<p>In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP mediated interactions involving emtricitabine and tenofovir with other medicinal products is low.</p>
<p>No clinically significant drug interactions have been observed between emtricitabine and famciclovir, indinavir, stavudine, tenofovir disoproxil fumarate, and zidovudine (see <a href="#table5">Tables 5</a> and <a href="#table6">6</a>). Similarly, no clinically significant drug interactions have been observed between tenofovir disoproxil fumarate and abacavir, efavirenz, emtricitabine, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirin, saquinavir/ritonavir, and tacrolimus in studies conducted in healthy volunteers (see <a href="#table7">Tables 7</a> and <a href="#table8">8</a>). </p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5 Drug Interactions:  Changes in Pharmacokinetic Parameters for Emtricitabine in the Presence of the Coadministered Drug<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">Emtricitabine Dose (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Emtricitabine Pharmacokinetic Parameters<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a> (90% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>All interaction studies conducted in healthy volunteers.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd><p class="First">↑ = Increase; ↓ = Decrease; <img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"> = No Effect; NA = Not Applicable</p></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Tenofovir DF</td>
<td class="Rrule" align="center">300 once daily × 7 days</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 20<br> (↑ 12 to ↑ 29)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Zidovudine</td>
<td class="Rrule" align="center">300 twice daily × 7 days</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 × 1</td>
<td class="Rrule" align="center">200 × 1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Famciclovir</td>
<td class="Rrule" align="center">500 × 1</td>
<td class="Rrule" align="center">200 × 1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Stavudine</td>
<td class="Rrule" align="center">40 × 1</td>
<td class="Rrule" align="center">200 × 1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="100%">
<caption><span>Table 6 Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Emtricitabine<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">Emtricitabine Dose (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Coadministered Drug Pharmacokinetic Parameters<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a> (90% CI)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>All interaction studies conducted in healthy volunteers.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd><p class="First">↑ = Increase; ↓ = Decrease; <img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"> = No Effect; NA = Not Applicable</p></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Tenofovir DF</td>
<td class="Rrule" align="center">300 once daily × 7 days</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Zidovudine</td>
<td class="Rrule" align="center">300 twice daily × 7 days</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">↑ 17<br> (↑ 0 to ↑ 38)</td>
<td class="Rrule" align="center">↑ 13<br> (↑ 5 to ↑ 20)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 × 1</td>
<td class="Rrule" align="center">200 × 1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Famciclovir</td>
<td class="Rrule" align="center">500 × 1</td>
<td class="Rrule" align="center">200 × 1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">Stavudine</td>
<td class="Rrule Toprule" align="center">40 × 1</td>
<td class="Rrule Toprule" align="center">200 × 1</td>
<td class="Rrule Toprule" align="center">6</td>
<td class="Rrule Toprule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule Toprule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule Toprule" align="center">NA</td>
</tr>
</tbody>
</table>
<a name="table7"></a><table width="100%">
<caption><span>Table 7 Drug Interactions:  Changes in Pharmacokinetic Parameters for Tenofovir<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> in the Presence of the Coadministered Drug</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Tenofovir Pharmacokinetic Parameters<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a><br> (90% CI)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Patients received VIREAD 300 mg once daily.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg">; NC = Not Calculated</p></dd>
<dt><a name="footnote-16" href="#footnote-reference-16">‡</a></dt>
<dd>Reyataz Prescribing Information</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Abacavir</td>
<td class="Rrule" align="center">300 once</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NC</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-16" href="#footnote-16" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">400 once daily × 14 days</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">↑ 14<br> (↑ 8 to ↑ 20)</td>
<td class="Rrule" align="center">↑ 24<br> (↑ 21 to ↑ 28)</td>
<td class="Rrule" align="center">↑ 22<br> (↑ 15 to ↑ 30)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (enteric-coated)</td>
<td class="Rrule" align="center">400 once</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (buffered)</td>
<td class="Rrule" align="center">250 or 400 once daily × 7 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz </td>
<td class="Rrule" align="center">600 once daily × 14 days</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Emtricitabine</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Entecavir</td>
<td class="Rrule" align="center">1 mg once daily × 10 days</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 three times daily × 7 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↑ 14<br> (↓ 3 to ↑ 33)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lamivudine</td>
<td class="Rrule" align="center">150 twice daily × 7 days</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/Ritonavir </td>
<td class="Rrule" align="center">400/100 twice daily × 14 days</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 32<br> (↑ 25 to ↑ 38)</td>
<td class="Rrule" align="center">↑ 51<br> (↑ 37 to ↑ 66)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Rrule" align="center">1250 twice daily × 14 days</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir/Ritonavir</td>
<td class="Rrule" align="center">1000/100 twice daily × 14 days</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 23<br> (↑ 16 to ↑ 30)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tacrolimus</td>
<td class="Rrule" align="center">0.05 mg/kg twice daily × 7 days</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">↑ 13<br>(↑ 1 to ↑ 27)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="100%">
<caption><span>Table 8 Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Tenofovir</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Coadministered Drug Pharmacokinetic Parameters<a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a><br> (90% CI)</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg">; NA = Not Applicable</p></dd>
<dt><a name="footnote-18" href="#footnote-reference-18">†</a></dt>
<dd>Reyataz Prescribing Information</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">‡</a></dt>
<dd>In HIV-infected subjects, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C<span class="Sub">min</span> values of atazanavir that were 2.3 and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">§</a></dt>
<dd>R-(active), S- and total methadone exposures were equivalent when dosed alone or with VIREAD.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">¶</a></dt>
<dd>Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">#</a></dt>
<dd>Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with VIREAD.</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">Þ</a></dt>
<dd>Increases in AUC and C<span class="Sub">min</span> are not expected to be clinically relevant; hence no dose adjustments are required when tenofovir DF and ritonavir-boosted saquinavir are coadministered.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Abacavir</td>
<td class="Rrule" align="center">300 once</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">↑ 12<br> (↓ 1 to ↑ 26)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-18" href="#footnote-18" class="Sup">†</a>
</td>
<td class="Rrule" align="center">400 once daily × 14 days</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">↓ 21<br> (↓ 27 to ↓ 14)</td>
<td class="Rrule" align="center">↓ 25<br> (↓ 30 to ↓ 19)</td>
<td class="Rrule" align="center">↓ 40<br> (↓ 48 to ↓ 32)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a href="#footnote-18" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Atazanavir/Ritonavir 300/100 once daily × 42 days</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↓ 28<br> (↓ 50 to ↑ 5)</td>
<td class="Rrule" align="center">↓ 25<a name="footnote-reference-19" href="#footnote-19" class="Sup">‡</a><br> (↓ 42 to ↓ 3)</td>
<td class="Rrule" align="center">↓ 23<a href="#footnote-19" class="Sup">‡</a><br> (↓ 46 to ↑ 10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz </td>
<td class="Rrule" align="center">600 once daily × 14 days</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Emtricitabine</td>
<td class="Rrule" align="center">200 once daily × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 20<br> (↑ 12 to ↑ 29)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 three times daily × 7 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓ 11<br> (↓ 30 to ↑ 12)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Entecavir</td>
<td class="Rrule" align="center">1 mg once daily × 10 days</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 13<br>(↑ 11 to ↑ 15)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lamivudine</td>
<td class="Rrule" align="center">150 twice daily × 7 days</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↓ 24<br> (↓ 34 to ↓ 12)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lopinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">Lopinavir/Ritonavir 400/100 twice daily × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">24</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methadone<a name="footnote-reference-20" href="#footnote-20" class="Sup">§</a>
</td>
<td class="Rrule" align="center">40–110 once daily × 14 days<a name="footnote-reference-21" href="#footnote-21" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">1250 twice daily × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">29</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">M8 metabolite</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oral Contraceptives<a name="footnote-reference-22" href="#footnote-22" class="Sup">#</a>
</td>
<td class="Rrule" align="center">Ethinyl Estradiol/ Norgestimate (Ortho-Tricyclen) Once daily × 7 days</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ribavirin</td>
<td class="Rrule" align="center">600 once</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Saquinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">Saquinavir/Ritonavir 1000/100 twice daily × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">32</td>
<td class="Rrule" align="center">↑ 22<br> (↑ 6 to ↑41)</td>
<td class="Rrule" align="center">↑ 29<a name="footnote-reference-23" href="#footnote-23" class="Sup">Þ</a><br> (↑ 12 to ↑ 48)</td>
<td class="Rrule" align="center">↑ 47<a href="#footnote-23" class="Sup">Þ</a><br> (↑ 23 to ↑ 76)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 23<br> (↑ 3 to ↑ 46)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tacrolimus</td>
<td class="Rrule" align="center">0.05 mg/kg twice daily × 7 days</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
</tbody>
</table>
<p>Following multiple dosing to HIV-negative subjects receiving either chronic methadone maintenance therapy or oral contraceptives, or single doses of ribavirin, steady state tenofovir pharmacokinetics were similar to those observed in previous studies, indicating lack of clinically significant drug interactions between these agents and VIREAD.</p>
<p>Coadministration of tenofovir disoproxil fumarate with didanosine results in changes in the pharmacokinetics of didanosine that may be of clinical significance. Table 9 summarizes the effects of tenofovir disoproxil fumarate on the pharmacokinetics of didanosine. Concomitant dosing of tenofovir disoproxil fumarate with didanosine buffered tablets or enteric-coated capsules significantly increases the C<span class="Sub">max</span> and AUC of didanosine. When didanosine 250 mg enteric-coated capsules were administered with tenofovir disoproxil fumarate, systemic exposures of didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions. The mechanism of this interaction is unknown. See <span class="Italics"><a href="#S7.1">Drug Interactions (7.1)</a></span> regarding use of didanosine with VIREAD.</p>
<a name="table9"></a><table width="100%">
<caption><span>Table 9 Drug Interactions:  Pharmacokinetic Parameters for Didanosine in the Presence of VIREAD</span></caption>
<col align="left" valign="middle" width="20%">
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Didanosine<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a> Dose (mg)/Method of Administration<a href="#footnote-24" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">VIREAD Method of Administration<a href="#footnote-24" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="2">% Difference (90% CI) vs. Didanosine  400 mg Alone, Fasted<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>Administration with food was with a light meal (~373 kcal, 20% fat).</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></p></dd>
<dt><a name="footnote-26" href="#footnote-reference-26">‡</a></dt>
<dd>Includes 4 subjects weighing &lt;60 kg receiving ddI 250 mg.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left" colspan="2"><span class="Bold">Buffered tablets</span></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once daily<a name="footnote-reference-26" href="#footnote-26" class="Sup">‡</a> × 7 days</td>
<td class="Rrule" align="left">Fasted 1 hour after didanosine</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑ 28<br> (↑ 11 to ↑ 48)</td>
<td class="Rrule" align="center">↑ 44<br> (↑ 31 to ↑ 59)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" colspan="2"><span class="Bold">Enteric coated capsules</span></td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, fasted</td>
<td class="Rrule" align="left">With food, 2 hours after didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 48<br> (↑ 25 to ↑ 76)</td>
<td class="Rrule" align="center">↑ 48<br> (↑ 31 to ↑ 67)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, with food</td>
<td class="Rrule" align="left">Simultaneously with didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 64<br> (↑ 41 to ↑ 89)</td>
<td class="Rrule" align="center">↑ 60<br> (↑ 44 to ↑ 79)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="left">With food, 2 hours after didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">↓ 10<br> (↓ 22 to ↑ 3)</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="left">Simultaneously with didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center"><img alt="Symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=truvada-03.jpg"></td>
<td class="Rrule" align="center">↑ 14<br> (0 to ↑ 31)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">250 once, with food</td>
<td class="Rrule" align="left">Simultaneously with didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">↓ 29<br> (↓ 39 to ↓ 18)</td>
<td class="Rrule" align="center">↓ 11<br> (↓ 23 to ↑ 2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.17"></a><p></p>
<h2>12.4	Microbiology</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.18"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Mechanism of Action</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.19"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5'-triphosphate is a weak inhibitor of mammalian DNA polymerase α, β, ε and mitochondrial DNA polymerase γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.20"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.21"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiviral Activity</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.22"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  In combination studies evaluating the cell culture antiviral activity of emtricitabine and tenofovir together, synergistic antiviral effects were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.23"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine: </span> The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells. The 50% effective concentration (EC<span class="Sub">50</span>) values for emtricitabine were in the range of 0.0013–0.64 µM (0.0003–0.158 µg/mL). In drug combination studies of emtricitabine with nucleoside reverse transcriptase inhibitors (abacavir, lamivudine, stavudine, zalcitabine, zidovudine), non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, nevirapine), and protease inhibitors (amprenavir, nelfinavir, ritonavir, saquinavir), additive to synergistic effects were observed. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC<span class="Sub">50</span> values ranged from 0.007–0.075 µM) and showed <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific activity against HIV-2 (EC<span class="Sub">50</span> values ranged from 0.007–1.5 µM).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.24"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The EC<span class="Sub">50</span> values for tenofovir were in the range of 0.04–8.5 µM. In drug combination studies of tenofovir with nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, zalcitabine, zidovudine), non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, nevirapine), and protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), additive to synergistic effects were observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G and O (EC<span class="Sub">50</span> values ranged from 0.5–2.2 µM) and showed <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific activity against HIV-2 (EC<span class="Sub">50</span> values ranged from 1.6 µM to 5.5 µM).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.25"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Resistance</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.26"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  HIV-1 isolates with reduced susceptibility to the combination of emtricitabine and tenofovir have been selected in cell culture. Genotypic analysis of these isolates identified the M184V/I and/or K65R amino acid substitutions in the viral RT.</p>
<p>In a clinical study of treatment-naive subjects <span class="Italics">[Study 934, see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>, resistance analysis was performed on HIV-1 isolates from all confirmed virologic failure subjects with &gt;400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation. Development of efavirenz resistance-associated substitutions occurred most frequently and was similar between the treatment arms. The M184V amino acid substitution, associated with resistance to EMTRIVA and lamivudine, was observed in 2/19 analyzed subjects isolates in the EMTRIVA + VIREAD group and in 10/29 analyzed subjects isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects have developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.27"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span>  Emtricitabine-resistant isolates of HIV-1 have been selected in cell culture and in vivo. Genotypic analysis of these isolates showed that the reduced susceptibility to emtricitabine was associated with a substitution in the HIV-1 RT gene at codon 184 which resulted in an amino acid substitution of methionine by valine or isoleucine (M184V/I).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.28"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  HIV-1 isolates with reduced susceptibility to tenofovir have been selected in cell culture. These viruses expressed a K65R substitution in RT and showed a 2–4 fold reduction in susceptibility to tenofovir.</p>
<p>In treatment-naive subjects, isolates from 8/47 (17%) analyzed subjects developed the K65R substitution in the VIREAD arm through 144 weeks; 7 occurred in the first 48 weeks of treatment and 1 at Week 96. In treatment-experienced subjects, 14/304 (5%) isolates from subjects failing VIREAD through Week 96 showed &gt;1.4 fold (median 2.7) reduced susceptibility to tenofovir. Genotypic analysis of the resistant isolates showed a substitution in the HIV-1 RT gene resulting in the K65R amino acid substitution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.29"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Cross Resistance</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.30"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine and Tenofovir Disoproxil Fumarate:</span>  Cross-resistance among certain nucleoside reverse transcriptase inhibitors (NRTIs) has been recognized. The M184V/I and/or K65R substitutions selected in cell culture by the combination of emtricitabine and tenofovir are also observed in some HIV-1 isolates from subjects failing treatment with tenofovir in combination with either lamivudine or emtricitabine, and either abacavir or didanosine. Therefore, cross-resistance among these drugs may occur in patients whose virus harbors either or both of these amino acid substitutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.31"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine: </span> Emtricitabine-resistant isolates (M184V/I) were cross-resistant to lamivudine and zalcitabine but retained susceptibility in cell culture to didanosine, stavudine, tenofovir, zidovudine, and NNRTIs (delavirdine, efavirenz, and nevirapine). HIV-1 isolates containing the K65R substitution, selected in vivo by abacavir, didanosine, tenofovir, and zalcitabine, demonstrated reduced susceptibility to inhibition by emtricitabine. Viruses harboring substitutions conferring reduced susceptibility to stavudine and zidovudine (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E), or didanosine (L74V) remained sensitive to emtricitabine. HIV-1 containing the K103N substitution associated with resistance to NNRTIs was susceptible to emtricitabine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.32"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate:</span>  HIV-1 isolates from patients (N=20) whose HIV-1 expressed a mean of 3 zidovudine-associated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir. Subjects whose virus expressed an L74V substitution without zidovudine resistance associated substitutions (N=8) had reduced response to VIREAD. Limited data are available for patients whose virus expressed a Y115F substitution (N=3), Q151M substitution (N=2), or T69 insertion (N=4), all of whom had a reduced response.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Emtricitabine:</span> In long-term oral carcinogenicity studies of emtricitabine, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/kg/day (31 times the human systemic exposure at the therapeutic dose). </p>
<p>Emtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test), mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> or mouse micronucleus assays.</p>
<p>Emtricitabine did not affect fertility in male rats at approximately 140-fold or in male and female mice at approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily dose. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended 200 mg daily dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Tenofovir Disoproxil Fumarate: </span> Long-term oral carcinogenicity studies of tenofovir disoproxil fumarate in mice and rats were carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in humans at the therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. At the high dose in female mice, liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased at exposures 16 times that in humans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.</p>
<p>Tenofovir disoproxil fumarate was mutagenic in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and negative in an in vitro bacterial mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, tenofovir disoproxil fumarate was negative when administered to male mice.</p>
<p>There were no effects on fertility, mating performance or early embryonic development when tenofovir disoproxil fumarate was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating through day seven of gestation. There was, however, an alteration of the estrous cycle in female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.4"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">Tenofovir and tenofovir disoproxil fumarate administered in toxicology studies to rats, dogs and monkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>. <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">Osteomalacia</span> observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown.</p>
<p>Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, phosphaturia, and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2–20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">Clinical Study 934 supports the use of TRUVADA tablets for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Additional data in support of the use of TRUVADA are derived from Study 903, in which lamivudine and tenofovir disoproxil fumarate (tenofovir DF) were used in combination in treatment-naive adults, and clinical Study 303 in which emtricitabine and lamivudine demonstrated comparable efficacy, safety and resistance patterns as part of multidrug regimens. For additional information about these studies, please consult the prescribing information for tenofovir DF and emtricitabine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Study 934</h2>
<p class="First">Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled multicenter study comparing emtricitabine + tenofovir DF administered in combination with efavirenz versus zidovudine/lamivudine fixed-dose combination administered in combination with efavirenz in 511 antiretroviral-naive subjects. From Weeks 96 to 144 of the study, subjects received TRUVADA with efavirenz in place of emtricitabine + tenofovir DF with efavirenz. Subjects had a mean age of 38 years (range 18–80), 86% were male, 59% were Caucasian and 23% were Black. The mean baseline CD4<span class="Sup">+</span> cell count was 245 cells/mm<span class="Sup">3</span> (range 2–1191) and median baseline plasma HIV-1 RNA was 5.01 log<span class="Sub">10</span> copies/mL (range 3.56–6.54). Subjects were stratified by baseline CD4<span class="Sup">+</span> cell count (&lt; or ≥200 cells/mm<span class="Sup">3</span>); 41% had CD4<span class="Sup">+</span> cell counts &lt;200 cells/mm<span class="Sup">3</span> and 51% of subjects had baseline viral loads &gt;100,000 copies/mL. Treatment outcomes through 48 and 144 weeks for those subjects who did not have efavirenz resistance at baseline are presented in Table 10.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10 Outcomes of Randomized Treatment at Week 48 and 144 (Study 934)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Outcomes</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 48</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 144</th>
</tr>
<tr class="Last">
<th align="center">FTC + TDF<br>+ EFV<br>(N=244)</th>
<th class="Lrule Rrule" align="center">AZT/3TC <br> + EFV<br> (N=243)</th>
<th class="Rrule" align="center">FTC + TDF<br>  + EFV<br> (N=227)<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a>
</th>
<th class="Rrule" align="center">AZT/3TC <br> + EFV<br> (N=229)<a href="#footnote-27" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>Subjects who were responders at Week 48 or Week 96 (HIV-1 RNA &lt;400 copies/mL) but did not consent to continue study after Week 48 or Week 96 were excluded from analysis.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">†</a></dt>
<dd>Subjects achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">‡</a></dt>
<dd>Includes confirmed viral rebound and failure to achieve confirmed &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">§</a></dt>
<dd>Includes lost to follow-up, subject withdrawal, noncompliance, protocol violation and other reasons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Responder<a name="footnote-reference-28" href="#footnote-28" class="Sup">†</a>
</td>
<td align="center">84%</td>
<td class="Lrule Rrule" align="center">73%</td>
<td class="Rrule" align="center">71%</td>
<td class="Rrule" align="center">58%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virologic failure<a name="footnote-reference-29" href="#footnote-29" class="Sup">‡</a>
</td>
<td align="center">2%</td>
<td class="Lrule Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Rebound</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Never suppressed</td>
<td align="center">0%</td>
<td class="Lrule Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change in antiretroviral regimen</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">&lt;1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Discontinued due to adverse event</td>
<td align="center">4%</td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinued for other reasons<a name="footnote-reference-30" href="#footnote-30" class="Sup">§</a>
</td>
<td align="center">10%</td>
<td class="Lrule Rrule" align="center">14%</td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">22%</td>
</tr>
</tbody>
</table>
<p>Through Week 48, 84% and 73% of subjects in the emtricitabine + tenofovir DF group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;400 copies/mL (71% and 58% through Week 144). The difference in the proportion of subjects who achieved and maintained HIV-1 RNA &lt;400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reasons in the zidovudine/lamivudine group in this open-label study. In addition, 80% and 70% of subjects in the emtricitabine + tenofovir DF group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;50 copies/mL through Week 48 (64% and 56% through Week 144). The mean increase from baseline in CD4<span class="Sup">+</span> cell count was 190 cells/mm<span class="Sup">3</span> in the emtricitabine + tenofovir DF group and 158 cells/mm<span class="Sup">3</span> in the zidovudine/lamivudine group at Week 48 (312 and 271 cells/mm<span class="Sup">3</span> at Week 144).</p>
<p>Through 48 weeks, 7 subjects in the emtricitabine + tenofovir DF group and 5 subjects in the zidovudine/lamivudine group experienced a new CDC Class C event (10 and 6 subjects through 144 weeks).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">The blue, capsule-shaped, film-coated, tablets contain 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (which is equivalent to 245 mg of tenofovir disoproxil), are debossed with "GILEAD" on one side and with "701" on the other side.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0805-1</td>
<td align="center">200 mg / 300 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">BLUE</td>
<td align="center">61958-0701</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First">Store at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F) (see USP Controlled Room Temperature).</p>
<ul>
<li>Keep container tightly closed</li>
<li>Dispense only in original container</li>
<li>Do not use if seal over bottle opening is broken or missing.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION and FDA-APPROVED PATIENT LABELING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p>Patients should be advised that:</p>
<ul>
<li>TRUVADA is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using TRUVADA.</li>
<li>The use of TRUVADA has not been shown to reduce the risk of transmission of HIV-1 to others through sexual contact or blood contamination. Patients should be advised to continue to practice safer sex and to use latex or polyurethane condoms to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions or blood. Patients should be advised never to re-use or share needles.</li>
<li>The long term effects of TRUVADA are unknown.</li>
<li>TRUVADA tablets are for oral ingestion only.</li>
<li>It is important to take TRUVADA with combination therapy on a regular dosing schedule to avoid missing doses.</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported. Treatment with TRUVADA should be suspended in any patients who develop clinical symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>All patients with HIV-1 should be tested for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) before initiating antiretroviral therapy.</li>
<li>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued TRUVADA.</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, has been reported in association with the use of VIREAD. TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. Dosing interval of TRUVADA may need adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>.</li>
<li>TRUVADA should not be coadministered with ATRIPLA, EMTRIVA, or VIREAD; or with drugs containing lamivudine, including Combivir (lamivudine/zidovudine), Epivir or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), or Trizivir (abacavir sulfate/lamivudine/zidovudine) <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>TRUVADA should not be administered with HEPSERA <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>Decreases in bone mineral density have been observed with the use of VIREAD. Bone monitoring should be considered in patients who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span> <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>].</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="S17.2"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling</span></p>
<p><span class="Bold">TRUVADA<span class="Sup">®</span> (tru-VAH-dah) tablets</span></p>
<p>Generic name:  emtricitabine and tenofovir disoproxil fumarate<br>(em tri SIT uh bean and te NOE' fo veer dye soe PROX il FYOU mar ate)</p>
<p>Read the Patient Information that comes with TRUVADA before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. You should stay under a healthcare provider's care when taking TRUVADA. <span class="Bold">Do not change or stop your medicine without first talking with your healthcare provider</span>. Talk to your healthcare provider or pharmacist if you have any questions about TRUVADA.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about TRUVADA?</span></p>
<ul>
<li>
<span class="Bold">Some people who have taken medicine like TRUVADA (nucleoside analogs) have developed a serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span></span> (build up of an acid in the blood). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be a medical emergency and may need to be treated in the hospital. <span class="Bold">Call your healthcare provider right away if you get the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</span><ul class="Disc">
<li>You feel very weak or tired.</li>
<li>You have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>.</li>
<li>You have trouble breathing.</li>
<li>You have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</li>
<li>You feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs.</li>
<li>You feel dizzy or lightheaded.</li>
<li>You have a fast or irregular heartbeat.</li>
</ul>
</li>
<li>
<span class="Bold">Some people who have taken medicines like TRUVADA have developed serious liver problems called hepatotoxicity</span>, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). <span class="Bold">Call your healthcare provider right away if you get the following signs or symptoms of liver problems.</span><ul class="Disc">
<li>Your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>).</li>
<li>Your urine turns dark.</li>
<li>Your bowel movements (stools) turn light in color.</li>
<li>You don't feel like eating food for several days or longer.</li>
<li>You feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</li>
<li>You have lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</li>
</ul>
</li>
<li>
<span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or liver problems</span> if you are female, very overweight (obese), or have been taking nucleoside analog medicines, like TRUVADA, for a long time.</li>
<li>
<span class="Bold">If you are also infected with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV),</span> you need close medical follow-up for several months after stopping treatment with TRUVADA. Follow-up includes medical exams and blood tests to check for HBV that could be getting worse. <span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, who take TRUVADA and then stop it, may get "flare-ups" of their <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. A "flare-up" is when the disease suddenly returns in a worse way than before.</span>
</li>
</ul>
<p><span class="Bold">What is TRUVADA?</span></p>
<p>TRUVADA is a type of medicine called an HIV-1 (human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus) nucleoside analog reverse transcriptase inhibitor (NRTI). TRUVADA contains 2 medicines, EMTRIVA<span class="Sup">®</span> (emtricitabine) and VIREAD<span class="Sup">®</span> (tenofovir disoproxil fumarate, or tenofovir DF) combined in one pill. TRUVADA is always used with other anti-HIV-1 medicines to treat people with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. TRUVADA is for adults age 18 and older. TRUVADA has not been studied in children under age 18 or adults over age 65.</p>
<p><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> destroys CD4<span class="Sup">+</span> T cells, which are important to the immune system. The immune system helps fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. After a large number of T cells are destroyed, <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> (AIDS) develops.</p>
<p>TRUVADA helps block HIV-1 reverse transcriptase, a chemical in your body (enzyme) that is needed for HIV-1 to multiply. TRUVADA lowers the amount of HIV-1 in the blood (viral load). TRUVADA may also help to increase the number of T cells (CD4<span class="Sup">+</span> cells). Lowering the amount of HIV-1 in the blood lowers the chance of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<p><span class="Bold">TRUVADA does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS. </span>The long-term effects of TRUVADA are not known at this time. People taking TRUVADA may still get <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> or other conditions that happen with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that develop because the immune system is weak. Some of these conditions are <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span>, and <span class="Italics">Mycobacterium avium complex</span> (MAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="Bold">It is very important that you see your healthcare provider regularly while taking TRUVADA.</span></p>
<p><span class="Bold">TRUVADA does not lower your chance of passing HIV-1 to other people through sexual contact, sharing needles, or being exposed to your blood. </span>For your health and the health of others, it is important to always practice safer sex by using a latex or polyurethane condom or other barrier to lower the chance of sexual contact with semen, vaginal secretions, or blood. Never use or share dirty needles.</p>
<p><span class="Bold">Who should not take TRUVADA?</span></p>
<ul>
<li>Do not take TRUVADA if you are allergic to TRUVADA or any of its ingredients. The active ingredients of TRUVADA are emtricitabine and tenofovir DF. See the end of this leaflet for a complete list of <a href="#ingredients">ingredients.</a>
</li>
<li>Do not take TRUVADA if you are already taking ATRIPLA<span class="Sup">®</span>, Combivir (lamivudine/zidovudine), EMTRIVA, Epivir or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), Trizivir (abacavir sulfate/lamivudine/zidovudine), or VIREAD because these medicines contain the same or similar active ingredients.</li>
<li>Do not take TRUVADA to treat your <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> if you are also taking HEPSERA<span class="Sup">®</span> to treat your HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p><a name="doc"></a><span class="Bold">What should I tell my healthcare provider before taking TRUVADA?</span></p>
<p><span class="Bold">Tell your healthcare provider if you:</span></p>
<ul>
<li>
<span class="Bold">are pregnant or planning to become pregnant. </span>We do not know if TRUVADA can harm your unborn child. You and your healthcare provider will need to decide if TRUVADA is right for you. If you use TRUVADA while you are pregnant, talk to your healthcare provider about how you can be on the TRUVADA Antiviral Pregnancy Registry.</li>
<li>
<span class="Bold">are breast-feeding. </span>You should not breast feed if you are HIV-positive because of the chance of passing the HIV virus to your baby. Also, it is not known if TRUVADA can pass into your breast milk and if it can harm your baby. If you are a woman who has or will have a baby, talk with your healthcare provider about the best way to feed your baby.</li>
<li><span class="Bold">have kidney problems or are undergoing kidney dialysis treatment.</span></li>
<li><span class="Bold">have bone problems.</span></li>
<li><span class="Bold">have liver problems including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take: </p>
<ul>
<li>Videx, Videx EC (didanosine). Tenofovir DF (a component of TRUVADA) may increase the amount of Videx in your blood. <span class="Bold">You may need to be followed more carefully if you are taking TRUVADA and Videx together</span>. Also, the dose of didanosine may need to be reduced.</li>
<li>Reyataz (atazanavir sulfate) or Kaletra (lopinavir/ritonavir). These medicines may increase the amount of tenofovir DF (a component of TRUVADA) in your blood, which could result in more side effects. You may need to be followed more carefully if you are taking TRUVADA and Reyataz or Kaletra together. TRUVADA may decrease the amount of Reyataz in your blood. If you are taking TRUVADA and Reyataz together, you should also be taking Norvir (ritonavir).</li>
</ul>
<p>Keep a complete list of all the medicines that you take. Make a new list when medicines are added or stopped. Give copies of this list to all of your healthcare providers and pharmacist <span class="Bold">every</span> time you visit your healthcare provider or fill a prescription.</p>
<p><span class="Bold">How should I take TRUVADA?</span></p>
<ul>
<li>Take TRUVADA exactly as your healthcare provider prescribed it. Follow the directions from your healthcare provider, exactly as written on the label.</li>
<li>The usual dose of TRUVADA is 1 tablet once a day. TRUVADA is always used with other anti-HIV-1 medicines. If you have kidney problems, you may need to take TRUVADA less often.</li>
<li>TRUVADA may be taken with or without a meal. Food does not affect how TRUVADA works. Take TRUVADA at the same time each day.</li>
<li>If you forget to take TRUVADA, take it as soon as you remember that day. <span class="Bold">Do not </span>take more than 1 dose of TRUVADA in a day. <span class="Bold">Do not</span> take 2 doses at the same time. Call your healthcare provider or pharmacist if you are not sure what to do. <span class="Bold">It is important that you do not miss any doses of TRUVADA or your anti-HIV-1 medicines.</span>
</li>
<li>When your TRUVADA supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to TRUVADA and become harder to treat.</li>
<li>Do not change your dose or stop taking TRUVADA without first talking with your healthcare provider. Stay under a healthcare provider's care when taking TRUVADA.</li>
<li>If you take too much TRUVADA, call your local poison control center or emergency room right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking TRUVADA?</span></p>
<ul>
<li>
<span class="Bold">Do not breast-feed. </span>See "<a href="#doc">What should I tell my healthcare provider before taking TRUVADA</a>?"</li>
<li>
<span class="Bold">Avoid doing things that can spread <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span></span> since TRUVADA does not stop you from passing the <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to others. 								<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes or razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection. </span>Always practice safer sex by using a latex or polyurethane condom or other barrier to reduce the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
</li>
<li>ATRIPLA, Combivir (lamivudine/zidovudine), EMTRIVA, Epivir or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine), Trizivir (abacavir sulfate/lamivudine/zidovudine), or VIREAD.<br><span class="Bold">TRUVADA should not be used with these medicines.</span>
</li>
<li>TRUVADA should not be used with HEPSERA.</li>
</ul>
<p><span class="Bold">What are the possible side effects of TRUVADA?</span></p>
<p><span class="Bold">TRUVADA may cause the following serious side effects</span> (see "<a href="#important">What is the most important information I should know about TRUVADA</a>?"):</p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span></span> (buildup of an acid in the blood). <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be a medical emergency and may need to be treated in the hospital. <span class="Bold">Call your doctor right away if you get signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. </span>(See "<a href="#important">What is the most important information I should know about TRUVADA</a>?")</li>
<li>
<span class="Bold">Serious liver problems (hepatotoxicity</span>)<span class="Bold">,</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). Call your healthcare provider right away if you get any signs of liver problems. (See "<a href="#important">What is the most important information I should know about TRUVADA</a>?")</li>
<li>
<span class="Bold">"Flare-ups" of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, </span>in which the disease suddenly returns in a worse way than before, can occur if you stop taking TRUVADA. Your healthcare provider will monitor your condition for several months after stopping TRUVADA if you have both HIV-1 and HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. TRUVADA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If you have advanced liver disease and stop treatment with TRUVADA, the "flare-up" of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B may cause your liver function to decline.</li>
<li>
<span class="Bold">Kidney problems.</span> If you have had kidney problems in the past or take other medicines that can cause kidney problems, your healthcare provider should do regular blood tests to check your kidneys.</li>
<li>
<span class="Bold">Changes in bone mineral density (thinning bones).</span> Laboratory tests show changes in the bones of patients treated with VIREAD, a component of TRUVADA. Some HIV patients treated with VIREAD developed thinning of the bones (<span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>) which could lead to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. If you have had bone problems in the past, your healthcare provider may need to do tests to check your bone mineral density or may prescribe medicines to help your bone mineral density. Additionally, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and softening of the bone (which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) may occur as a consequence of kidney problems.</li>
</ul>
<p>Other side effects with TRUVADA when used with other anti-HIV-1 medicines include:</p>
<ul>
<li>Changes in body fat have been seen in some patients taking TRUVADA and other anti-HIV-1 medicines. These changes may include increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breast, and around the main part of your body (trunk). Loss of fat from the legs, arms and face may also happen. The cause and long term health effect of these conditions are not known at this time.</li>
<li>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS), signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms. If you notice any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, please inform your doctor immediately.</li>
</ul>
<p>The most common side effects of EMTRIVA or VIREAD when used with other anti-HIV-1 medicines are:  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, sleeping problems, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Additional side effects are <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, kidney problems (including decline or failure of kidney function), <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the liver, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, or throat), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, intestinal gas, and high volume of urine and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> caused by kidney problems. <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span> and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, and softening of the bone (which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) as a consequence of kidney problems have been reported. <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span> (small spots or freckles) may also happen with TRUVADA.</p>
<p>These are not all the side effects of TRUVADA. If you have questions about side effects, ask your healthcare provider. Report any new or continuing symptoms to your healthcare provider right away. Your healthcare provider may be able to help you manage these side effects.</p>
<p><span class="Bold">How do I store TRUVADA?</span></p>
<ul>
<li><span class="Bold">Keep TRUVADA and all other medicines out of reach of children.</span></li>
<li>Store TRUVADA at room temperature 77 °F (25 °C).</li>
<li>Keep TRUVADA in its original container and keep the container tightly closed.</li>
<li>Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away make sure that children will not find them.</li>
</ul>
<p><span class="Bold">General information about TRUVADA:</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use TRUVADA for a condition for which it was not prescribed. Do not give TRUVADA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about TRUVADA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about TRUVADA that is written for health professionals. For more information, you may also call 1-800-GILEAD-5 or access the TRUVADA website at www.TRUVADA.com.</p>
<p>Do not use TRUVADA if seal over bottle opening is broken or missing.</p>
<p><a name="ingredients"></a><span class="Bold">What are the ingredients of TRUVADA?</span></p>
<p><span class="Bold">Active Ingredients:</span>  emtricitabine and tenofovir disoproxil fumarate  </p>
<p><span class="Bold">Inactive Ingredients:</span>  Croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch (gluten free). The tablets are coated with Opadry II Blue Y-30-10701 containing FD&amp;C Blue #2 aluminum lake, hydroxypropyl methylcellulose 2910, lactose monohydrate, titanium dioxide, and triacetin.</p>
<p><span class="Bold">R<span class="Sub">x</span> Only</span></p>
<p>TRUVADA, EMTRIVA, HEPSERA and VIREAD are registered trademarks of Gilead Sciences, Inc. ATRIPLA is a trademark of Bristol-Myers Squibb &amp; Gilead Sciences, LLC. All other trademarks referenced herein are the property of their respective owners.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Tablet, Label</span></p>
<p>NDC 53808-0805-1</p>
<p><span class="Bold">Truvada<span class="Sup">®</span></span></p>
<p><span class="Bold">(emtricitabine and tenofovir<br>disoproxil fumarate)<br>Tablets</span></p>
<p>30 tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Tablet, Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0b3d18b-7e5d-49ea-bcaf-8408414e8094&amp;name=Truvada(Gilead).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRUVADA 		
					</strong><br><span class="contentTableReg">emtricitabine and tenofovir disoproxil fumarate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0805(NDC:61958-0701)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EMTRICITABINE</strong> (emtricitabine) </td>
<td class="formItem">EMTRICITABINE</td>
<td class="formItem">200 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TENOFOVIR DISOPROXIL FUMARATE</strong> (tenofovir) </td>
<td class="formItem">TENOFOVIR DISOPROXIL FUMARATE</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GILEAD;701</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0805-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021752</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>877e3186-0c6f-47e4-b946-2fe53d80ef12</div>
<div>Set id: d0b3d18b-7e5d-49ea-bcaf-8408414e8094</div>
<div>Version: 1</div>
<div>Effective Time: 20100413</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
